Chen X, Zhou YN, Lu XZ, Li RJ, Xiong YF, Sheng X, Zhu WW. Cognitive dysfunction in schizophrenia patients caused by down-regulation of γ-aminobutyric acid receptor subunits. World J Psychiatry 2024; 14(6): 784-793 [DOI: 10.5498/wjp.v14.i6.784]
Corresponding Author of This Article
Wei-Wei Zhu, MM, Associate Chief Physician, Department of Sleep Disorders and Neurosis, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, No. 427, Section 3, Furong Middle Road, Yuhua District, Changsha 410007, Hunan Province, China. q1640809558@163.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xi Chen, Ya-Nan Zhou, Ren-Jiao Li, Xia Sheng, Department of Child and Adolescent Psychiatric, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan Province, China
Xiao-Zi Lu, Department of Psychiatry, Qingdao Mental Health Center, Qingdao 266034, Shandong Province, China
Yi-Fan Xiong, Department of Psychiatry, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan Province, China
Wei-Wei Zhu, Department of Sleep Disorders and Neurosis, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan Province, China
Author contributions: Chen X performed the majority of experiments and wrote the manuscript; Zhou YN and Lu XZ designed the study and corrected the manuscript; Li RJ is involved in analytical tools; Xiong YF and Sheng X participated to the collection of the human material; Zhu WW served as scientific advisor and participate to the collection of human material.
Institutional review board statement: The study was approved by the ethics committee of Brain Hospital of Hunan Province (Approval No. 2023338).
Informed consent statement: All patients gave informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at q1640809558@163.com.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Wei Zhu, MM, Associate Chief Physician, Department of Sleep Disorders and Neurosis, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, No. 427, Section 3, Furong Middle Road, Yuhua District, Changsha 410007, Hunan Province, China. q1640809558@163.com
Received: March 7, 2024 Revised: April 25, 2024 Accepted: May 10, 2024 Published online: June 19, 2024 Processing time: 104 Days and 4.3 Hours
Abstract
BACKGROUND
The expression pattern of gamma aminobutyric acid (GABA) receptor subunits are commonly altered in patients with schizophrenia, which may lead to nerve excitation/inhibition problems, affecting cognition, emotion, and behavior.
AIM
To explore GABA receptor expression and its relationship with schizophrenia and to provide insights into more effective treatments.
METHODS
This case-control study enrolled 126 patients with schizophrenia treated at our hospital and 126 healthy volunteers who underwent physical examinations at our hospital during the same period. The expression levels of the GABA receptor subunits were detected using 1H-magnetic resonance spectroscopy. The recognized cognitive battery tool, the MATRICS Consensus Cognitive Battery, was used to evaluate the scores for various dimensions of cognitive function. The correlation between GABA receptor subunit downregulation and schizophrenia was also analyzed.
RESULTS
Significant differences in GABA receptor subunit levels were found between the case and control groups (P < 0.05). A significant difference was also found between the case and control groups in terms of cognitive function measures, including attention/alertness and learning ability (P < 0.05). Specifically, as the expression levels of GABRA1 (α1 subunit gene), GABRB2 (β2 subunit gene), GABRD (δ subunit), and GABRE (ε subunit) decreased, the severity of the patients’ condition increased gradually, indicating a positive correlation between the downregulation of these 4 receptor subunits and schizophrenia (P < 0.05). However, the expression levels of GABRA5 (α5 subunit gene) and GABRA6 (α6 subunit gene) showed no significant correlation with schizophrenia (P > 0.05).
CONCLUSION
Downregulation of the GABA receptor subunits is positively correlated with schizophrenia. In other words, when GABA receptor subunits are downregulated in patients, cognitive impairment becomes more severe.
Core Tip: The levels of gamma-aminobutyric acid (GABA) receptor subunits differ between the brains of patients with schizophrenia and those of healthy individuals. Patients with schizophrenia show cognitive impairments due to problems with attention, memory, social cognition, and executive functions. Furthermore, downregulation of the GABA receptor subunits GABRA1, GABRB1, GABRD, and GABRE is positively correlated with declining cognitive function in schizophrenia patients. No significant correlation was found between the subunit expression levels of GABRA5 and GABRA6.
Citation: Chen X, Zhou YN, Lu XZ, Li RJ, Xiong YF, Sheng X, Zhu WW. Cognitive dysfunction in schizophrenia patients caused by down-regulation of γ-aminobutyric acid receptor subunits. World J Psychiatry 2024; 14(6): 784-793
Schizophrenia is a complex and devastating genetic psychiatric disorder worldwide, with high relapse and disability rates and a lifelong prevalence of 1%[1]. It is primarily characterized by disturbances in perception, thought, emotion, and behavior, with discoordination between the environment and mental activities[2]. It often begins in early adulthood, showing a slow and protracted course[3]. Some patients may experience a cognitive decline, which not only causes great suffering to the patients and their families, but also imposes a heavy economic burden on society.
Schizophrenia has complex clinical features, including positive (delusions, hallucinations, and thought disorders) and negative symptoms (blunted affect and social withdrawal)[4]. Cognitive impairment, including attention, working memory, executive function, and social cognition, is a core symptom that includes both the psychological and social aspects of cognition[5]. There is a strong correlation between cognitive impairment and long-term outcomes in patients with schizophrenia, as cognitive impairment appears before other psychiatric symptoms[6]. Therefore, cognitive function can be used to predict disease progression and treatment response to treatment[7]. In recent years, patients with cognitive impairment have received increasing attention.
Gamma aminobutyric acid (GABA) is a primary inhibitory neurotransmitter[8], found in approximately 50% of central synapses, which plays an important role in controlling neuronal excitability[9]. In addition to its distribution in various parts of the brain, GABA is associated with a variety of higher brain functions such as attention, working memory, emotions, and motor inhibition. The hypothesis of GABA deficiency in schizophrenia has been established over the past 30 years[10]. In 1972, Roberts proposed, for the first time, a correlation between schizophrenia and GABA system deficiency through his study on the interaction between GABA and DA in the basal ganglia[11]. Based on this, other researchers have established a theory of the interactions between GABA and dopamine in the striatum and marginal system, suggesting a weakened inhibitory effect of GABA on dopamine activity, leading to abnormal behavior[12]. Numerous studies have implicated the GABAergic neurotransmitter system in the pathogenesis of schizophrenia, according to numerous studies[13].
The association between GABA receptor gene clusters and schizophrenia has become a popular research topic in recent years[14]. Currently, several genes related to the GABA hypothesis of schizophrenia have received increasing attention, including GABRA1 (α1 subunit gene), GABRB2 (β2 subunit gene), GABRA5 (α5 subunit gene), GABRA6 (α6 subunit gene), GABRD (δ subunit), and GABRE (ε subunit)[15-17]. This study aimed to investigate the relationship between schizophrenia and the downregulation of GABA receptor subunits and to analyze how GABA receptor subunit expression levels correlate with schizophrenia symptoms and severity.
MATERIALS AND METHODS
General information
Data from 196 patients with schizophrenia who were admitted in our hospital from March 2022 to August 2023 were collected retrospectively. A total of 126 patients were selected as the case group based on the inclusion and exclusion criteria, while 126 healthy volunteers matched for age, sex, and education level, who underwent physical examination at our hospital in the same time period were randomly selected as the healthy control group. Data on age, sex, body mass index (BMI), education, living environment, type of schizophrenia, Brief Psychiatric Rating Scale (BPRS) score, smoking history, drinking history, and complications were collected for both groups.
Inclusion and exclusion criteria
The inclusion criteria for schizophrenia patients were[18]: (1) Patients diagnosed with schizophrenia in accordance with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders[19]; (2) Age 18-50 years, with no abnormalities in a routine blood examination; and (3) The main type of schizophrenia was the paranoid type. Exclusion criteria were as follows: (1) Patients with diabetes, thyroid disease, hypertension, cardiovascular disease, or other diseases that could adversely affect their microbiota; (2) Recent diarrhea and pregnancy or breastfeeding; and (3) Over one month of olanzapine, aripiprazole, quetiapine, and haloperidol administration.
The inclusion criteria for healthy controls were as follows: (1) No mental illness; (2) 18-50 years old; and (3) Primary school education or above, able to understand the research content. The exclusion criteria were: (1) Mental retardation or other serious mental disorders; (2) Organic brain or other serious somatic diseases; (3) History of drug or alcohol abuse; and (4) Mental retardation.
Detection of GABA receptor subunit levels
Blood samples were collected from patients with schizophrenia and healthy controls to determine the expression levels of GABA receptor subunits. The expression levels of GABA receptor subunits were detected using 1H-magnetic resonance spectroscopy (1H-MRS), at each visit, using the same 1H-MRS pulse sequences and equipment. By comparing the differences in GABA receptor subunit expression levels between patients with schizophrenia and healthy controls, further analyses were conducted to determine their relevance to schizophrenia. Additionally, the relationship between GABA receptor subunit expression levels and disease progression was analyzed based on the severity of patients’ symptoms.
Cognitive function scores
The first step in assessing the cognitive function scores was to determine whether patients were conscious. The severity of consciousness impairment was evaluated using the MATRICS Consensus Cognitive Battery (MCCB). MCCB Data Quality Assurance was assured by ensuring that each tester who interacted with the patients was trained in the administration and scoring of the MCCB through video and group sessions. If the patient was conscious, cognitive dysfunction was assessed using the BPRS[20]. Examination results can be used to determine whether patients have cognitive dysfunction and to further assess their cognitive function.
Statistical analysis
Statistical software (SPSS 26.0) was used to analyze the data. Continuous data is represented as the mean ± SD, and comparisons were conducted using the t-test. Categorical data is represented in the form of [n (%)], and comparisons were made using the χ2 test. Statistical significance was set at P < 0.05.
RESULTS
Comparison of baseline data results
As shown in Table 1, both the case and control groups were demographically and clinically similar. Baseline data, including age, sex, BMI, living environment, comorbidities, and years of education, did not show statistically significant differences (P > 0.05) between the two groups. A flowchart of the study is shown in Figure 1.
Comparison of GABA receptor subunit expression levels
As shown in Table 2, in contrast to healthy controls, patients with schizophrenia showed downregulated expression of GABA receptor subunits, which correlated with the risk of schizophrenia. In schizophrenia patients, GABRA1, GABRB2, GABRD, and GABRE expression levels were significantly lower than those in the healthy control group (P < 0.05), whereas the expression levels of the GABRA5 and GABRA6 subunits were not significantly different from those in the healthy control group (P > 0.05).
Table 2 Relative changes in gamma aminobutyric acid receptor subunit expression levels in the schizophrenia group.
Receptor subunit
FC
P value
GABRA1
-
< 0.001
GABRB2
-
< 0.001
GABRD
-
< 0.001
GABRE
-
< 0.001
GABRA5
0
0.993
GABRA6
0
0.991
Comparison of cognitive scores
Figure 2 shows a comparison of cognitive scores between the two groups. The case group scored significantly lower than the healthy control group (P < 0.001) in all four cognitive domains. The ability to process information quickly, maintain working memory, learn words, and solve problems is a part of the cognitive process. A significant difference was observed between the two groups in the visual learning domain of visual learning (P = 0.026). However, there were no significant differences in the attention/alertness domains (P = 0.73).
Figure 2 Comparative analysis of cognitive scores between the two groups.aP < 0.05, bP < 0.01, NS: Not significant.
Correlation analysis between downregulation of GABA receptor subunits and cognitive behavior in patients with schizophrenia
In this study, we examined the correlation between four GABA receptor subunits, with significant differences between the two groups of patients, and six cognitive domains of the MCCB (ability to process information efficiently, be attentive, maintain working memory, learn words, acquire visual perception, reason, and solve problems). In healthy controls, there was no correlation between the downregulation of GABA receptor subunits and cognitive function (P > 0.05).
Correlation analysis of GABA receiver subunit downregulation and information processing speed
Table 3 shows a positive correlation between information processing speed and the downregulation of the four receptor subunits in schizophrenia patients, with correlation coefficients for GABRA1 (r = 0.871, P = 0.023), GABRB2 (r = 0.731, P = 0.016), GABRD (r = 0.641, P = 0.032), and GABRE (r = 0.543, P = 0.018).
Table 3 Correlation analysis of gamma aminobutyric acid receptor subunit downregulation and information processing speed in MATRICS Consensus Cognitive Battery Cognitive Scores.
Receptor subunit
Information processing speed
r value
P value
GABRA1
1.375
0.023
GABRB2
2.625
0.016
GABRD
1.190
0.032
GABRE
5.364
0.018
Correlation analysis of GABA receiver subunit downregulation and verbal learning
As shown in Table 4, GABRA1, GABRB2, GABRD, and GABRE were not significantly correlated with word learning (P > 0.05) and only GABRA1 was downregulated (r = 0.734, P = 0.023).
Table 4 Correlation analysis gamma aminobutyric acid receptor subunit downregulation and verbal learning in MATRICS Consensus Cognitive Battery Cognitive Scores.
Receptor subunit
Verbal learning
r value
P value
GABRA1
0.734
0.023
GABRB2
0.075
0.773
GABRD
0.128
0.639
GABRE
0.079
0.833
Correlation analysis of GABA receiver subunit downregulation and working memory
As shown in Table 5, the downregulation of GABRA1 (r = 0.467, P = 0.047) and GABRB2 (r = 0.734, P = 0.023) was significantly positively correlated with working memory, while GABRD and GABRE were not correlated (P > 0.05).
Table 5 Correlation analysis of gamma aminobutyric acid receptor subunit downregulation and working memory in MATRICS Consensus Cognitive Battery Cognitive Scores.
Receptor subunit
Working memory
r value
P value
GABRA1
0.467
0.047
GABRB2
0.623
0.032
GABRD
0.099
0.833
GABRE
0.229
0.681
Correlation analysis of GABA receptor subunit downregulation and attention/vigilance visual learning
As shown in Table 6, only the GABRE (r = 0.532, P = 0.038) was associated with attention/vigilance in visual learning. GABRA1, GABRB2, and GABRD levels were positively correlated (P > 0.05).
Table 6 Correlation analysis of gamma aminobutyric acid receptor subunit downregulation and attention/vigilance visual learning in MATRICS Consensus Cognitive Battery Cognitive Scores.
Receptor subunit
Attention/vigilance visual learning
r value
P value
GABRA1
0.667
0.199
GABRB2
0.210
0.612
GABRD
0.261
0.609
GABRE
0.532
0.038
Correlation analysis of GABA receptor subunit downregulation and reasoning and problem solving
As shown in Table 7, GABRB2 (r = 0.992, P = 0.098), GABRD (r = 1.386, P < 0.001), and GABRE (r = 0.747, P = 0.004) were positively associated with reasoning and problem solving, whereas GABRA1 and GABRA1 were not correlated (P > 0.05).
Table 7 Correlation analysis of gamma aminobutyric acid receptor subunit downregulation and reasoning and problem solving in MATRICS Consensus Cognitive Battery Cognitive Scores.
Receptor subunit
Reasoning and problem solving
r value
P value
GABRA1
0.651
0.222
GABRB2
0.992
0.098
GABRD
1.386
< 0.001
GABRE
0.747
0.004
Correlation analysis of GABA receptor subunit downregulation and social cognition
As shown in Table 8, GABRB2 and GABRE were not significantly correlated with social cognition (P > 0.05). However, GABRA1 (r = 0.871, P = 0.006) and GABRD were significantly downregulated (r = 0.752, P = 0.049).
Table 8 Correlation analysis of gamma aminobutyric acid receptor subunit downregulation and social cognition in MATRICS Consensus Cognitive Battery Cognitive Scores.
Receptor subunit
Social cognition
r value
P value
GABRA1
0.871
0.006
GABRB2
0.152
0.707
GABRD
0.752
0.049
GABRE
0.468
0.360
DISCUSSION
In schizophrenia, a person’s senses, emotions, and behaviors are chronically and severely affected[21]. Individuals with schizophrenia have impaired ability to distinguish reality from imagination[22]. It may be difficult for them to engage in normal social behaviors because of their slow responses and behavioral withdrawal. Medical professionals classify schizophrenia as a disorder rather than a disease by medical professionals[23,24]. Most cases occur in young or primed individuals. It includes physical, mental, emotional, and behavioral disorders; however, the patient has no evidence of coma or mental retardation[25,26]. The pathogenesis of schizophrenia is complex and various hypotheses have been proposed. Recent studies have gradually shifted classical focus from the dopamine hypothesis to the GABA hypothesis. Signal transmission between most nerve cells in the central nervous system is primarily mediated by glutamate excitation and GABA inhibition mode[27]. GABA is produced from glutamate under the action of glutamate decarboxylase, and is abundantly expressed in the central nervous system[28]. Cl- are pumped out through the Na+/K+/Cl- pump transporter, which reduces the intracellular Cl- concentration and causes the hyperpolarization of neurons. Failure to maintain the glutamate-GABA balance may be related to schizophrenia, epilepsy, and anxiety[29]. Glutamate-GABA regulates the neuronal excitation-inhibition balance, which can cause neurodegenerative diseases and cognitive impairment[30]. Reversing GABA imbalance, inhibiting the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway, and inhibiting the release of interleukin-6 and tumor necrosis factor-alpha can improve cognitive impairment[31].
Patients with schizophrenia often experience cognitive impairments, such as difficulty integrating information, memory loss, and difficulty paying attention. Most individuals with cognitive dysfunction further experience memory decline as a primary symptom[32]. In addition, schizophrenia impairs executive function, visuospatial ability, comprehension, and numeracy. Age affects both general and social cognition[33]. The incidence of cognitive dysfunction increases with the aging population grows[34]. Several clinical studies have demonstrated a correlation between schizophrenia and cognitive function. Interventions targeting cognition, emotions, and social aspects have shown promising results[35]. This study observed a substantial decline in various cognitive aspects of patients with schizophrenia. Compared to healthy individuals, we observed impairments in learning, memory, fine motor skills, social cognition, working memory, category fluency, information processing, and kinetic energy. These results suggest an association between cognitive function and schizophrenia, similar to the results of the above study.
In addition, this study found that the downregulation of the GABA receptor subunit strongly affects schizophrenia symptoms and the risk of development. This finding supports the important role of the GABA system in the pathogenesis of schizophrenia, which is consistent with previous studies[36]. GABA is one of the most important inhibitory neurotransmitters in the central nervous system and plays a neuroregulatory role by binding to its receptors[37]. Changes in the expression of GABA receptor subunits may affect the inhibitory effect on neurons, leading to a variety of symptoms in patients with schizophrenia. According to these results, the downregulation of GABRA1, GABRB2, GABRD, GABRE, and other subunits may affect GABA receptor function, thereby affecting neuronal inhibitory effects[38]. Such changes may promote neuronal instability, leading to abnormalities in thinking, emotions, and behavior in people with schizophrenia. In addition, the expression levels of GABA receptor subunits may also be influenced by environmental factors, such as drugs, diet, and stress, which may also be involved in the pathogenesis of schizophrenia.
Limitations
This study has several limitations. Firstly, we only explored the correlation between GABA receptor subunits and schizophrenia in terms of gene expression, and the small sample size led to genetic analysis being the only method used to determine the results. Therefore, our study is only in the initial stages of exploring the relationships between genetic alterations. More comprehensive studies on these genes are needed to determine their exact roles in schizophrenia. Furthermore, other possible factors (such as environmental factors and nerve cell apoptosis, etc.) were not investigated. The pathogenesis of schizophrenia can be understood better by examining the effects of various factors. Further research is required to determine the interactions between different GABA receptor subunits and their effects on schizophrenia.
CONCLUSION
In conclusion, this study found that the downregulation of GABA receptor subunits is closely related to the risk and symptom severity of schizophrenia, providing a new perspective to further understand the pathogenesis of schizophrenia. Future studies are needed to further investigate the abnormal expression levels and function of GABA receptor subunits and the relationship between GABA receptor subunits and environmental factors, nerve cell apoptosis, and other factors to reveal the pathogenesis of schizophrenia more comprehensively. At the same time, the development of therapeutic strategies targeting GABA receptor subunits also needs further research and practice. Overall, the results of this study suggests that the downregulation of GABA receptor subunits is closely associated with the risk of onset and symptom severity in schizophrenia. These findings contribute to a deeper understanding of schizophrenia pathogenesis and provide a theoretical basis for developing new treatment strategies. Researchers must account for the effects of various factors on schizophrenia to better understand its pathogenesis.
Footnotes
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Psychiatry
Country of origin: China
Peer-review report’s classification
Scientific Quality: Grade C
Novelty: Grade B
Creativity or Innovation: Grade B
Scientific Significance: Grade B
P-Reviewer: Harnett NG, United States S-Editor: Wang JJ L-Editor: A P-Editor: Chen YX
Thompson SM. Modulators of GABA(A) receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future.Neuropsychopharmacology. 2024;49:83-95.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1][Reference Citation Analysis (0)]
Tarrés-Gatius M, López-Hill X, Miquel-Rio L, Castarlenas L, Fabius S, Santana N, Vilaró MT, Artigas F, Scorza MC, Castañé A. Discrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like models.Neuropharmacology. 2022;213:109079.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1][Cited by in F6Publishing: 1][Article Influence: 0.5][Reference Citation Analysis (0)]
Sharmin D, Mian MY, Marcotte M, Prevot TD, Sibille E, Witkin JM, Cook JM. Synthesis and Receptor Binding Studies of α5 GABA(A)R Selective Novel Imidazodiazepines Targeted for Psychiatric and Cognitive Disorders.Molecules. 2023;28.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Nicoletti F, Di Menna L, Iacovelli L, Orlando R, Zuena AR, Conn PJ, Dogra S, Joffe ME. GPCR interactions involving metabotropic glutamate receptors and their relevance to the pathophysiology and treatment of CNS disorders.Neuropharmacology. 2023;235:109569.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 10][Reference Citation Analysis (0)]
Mueller FS, Amport R, Notter T, Schalbetter SM, Lin HY, Garajova Z, Amini P, Weber-Stadlbauer U, Markkanen E. Deficient DNA base-excision repair in the forebrain leads to a sex-specific anxiety-like phenotype in mice.BMC Biol. 2022;20:170.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
McCoy AM, Prevot TD, Mian MY, Cook JM, Frazer A, Sibille EL, Carreno FR, Lodge DJ. Positive Allosteric Modulation of α5-GABAA Receptors Reverses Stress-Induced Alterations in Dopamine System Function and Prepulse Inhibition of Startle.Int J Neuropsychopharmacol. 2022;25:688-698.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Lee MT, Mouri A, Kubota H, Lee HJ, Chang MH, Wu CY, Knutson DE, Mihovilovic M, Cook J, Sieghart W, Nabeshima T, Chiou LC. Targeting α6GABA(A) receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal models.Biomed Pharmacother. 2022;150:113022.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1][Cited by in F6Publishing: 1][Article Influence: 0.5][Reference Citation Analysis (0)]
Gawande DY, S Narasimhan KK, Shelkar GP, Pavuluri R, Stessman HAF, Dravid SM. GluN2D Subunit in Parvalbumin Interneurons Regulates Prefrontal Cortex Feedforward Inhibitory Circuit and Molecular Networks Relevant to Schizophrenia.Biol Psychiatry. 2023;94:297-309.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 4][Reference Citation Analysis (0)]
Gaebler AJ, Fakour N, Stöhr F, Zweerings J, Taebi A, Suslova M, Dukart J, Hipp JF, Adhikari BM, Kochunov P, Muthukumaraswamy SD, Forsyth A, Eggermann T, Kraft F, Kurth I, Paulzen M, Gründer G, Schneider F, Mathiak K. Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI.Transl Psychiatry. 2023;13:59.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 4][Reference Citation Analysis (0)]
Falker-Gieske C, Bennewitz J, Tetens J. Structural variation and eQTL analysis in two experimental populations of chickens divergently selected for feather-pecking behavior.Neurogenetics. 2023;24:29-41.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
de Bartolomeis A, De Simone G, De Prisco M, Barone A, Napoli R, Beguinot F, Billeci M, Fornaro M. Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment.Mol Psychiatry. 2023;28:2811-2825.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1][Cited by in F6Publishing: 7][Article Influence: 7.0][Reference Citation Analysis (0)]
Vecera CM, C Courtes A, Jones G, Soares JC, Machado-Vieira R. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.Pharmaceuticals (Basel). 2023;16.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Lee M, Cernvall M, Borg J, Plavén-Sigray P, Larsson C, Erhardt S, Sellgren CM, Fatouros-Bergman H, Cervenka S. Cognitive Function and Variability in Antipsychotic Drug-Naive Patients With First-Episode Psychosis: A Systematic Review and Meta-Analysis.JAMA Psychiatry. 2024;.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 3][Reference Citation Analysis (0)]
Bampali K, Koniuszewski F, Silva LL, Rehman S, Vogel FD, Seidel T, Scholze P, Zirpel F, Garon A, Langer T, Willeit M, Ernst M. Tricyclic antipsychotics and antidepressants can inhibit α5-containing GABA(A) receptors by two distinct mechanisms.Br J Pharmacol. 2022;179:3675-3692.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Raymann S, Schalbetter SM, Schaer R, Bernhardt AC, Mueller FS, Meyer U, Weber-Stadlbauer U. Late prenatal immune activation in mice induces transgenerational effects via the maternal and paternal lineages.Cereb Cortex. 2023;33:2273-2286.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
